NR 546 Antidepressant and Mood Stabilizer Medication Table

Indication, starting dose, target symptoms, and affected neurotransmitters Half-life (T1/2) CYP450 enzyme Notes/Notable side effects/Precautions SSRIs Citalopram (Celexa) Indication  Depression  PMDD  OCD  Panic d/o  GAD  PTSD  Social anxiety d/o Neurotransmitter  Serotonin Target symptoms  Depressed mood  Anxiety  Panic attacks, avoidant behavior, reexperiencing, hyperarousal  Sleep disturbance, insomnia and hypersomnia Half-life 23-45 hour CYP450  Weak inhibitor of CYP450 2D6  Metabolized by CYPf450 3A4 and 2C19  Sexual dysfunction  Decreased appetite, n/d, constipation, dry mouth  Dose dependent insomnia, sedation, agitation, tremors, headache,dizzy  Pt with bipolar or psychotic d/o may be more vulnerable to CNS-activating actions of SSRIs  Sweating  Bruising and rare bleeding  Rare hyponatremia  Syndrome of inappropriate antidiuretic hormone secretion  Rare seizures, induction of mania, activation of suicidal ideation Escitalopram (Lexapro) Indication  MDD 12+  GAD  Panic d/o  OCD  PTSD  Social anxiety d/o  PMDD Neurotransmitter  Serotonin Half-life 27-32 hours CYP450 Substrate for CYP450 and 3A4 No significant actions on CYP450 enzymes  Sexual dysfunction ED, delayed ejaculation, decreased sexual desire, anorgasmia  Decreased appetite, n/d, constipation, dry mouth  Insomnia and sedation, agitation, tremors, headache, dizzy  Pt with bipolar or psychotic d/o may be more vulnerable to CNS-activating actions of SSRIs  Sweating  Rare hyponatremia  Syndrome of inappropriate antidiuretic hormone Target symptoms  Depressed mood  Anxiety  Panic attacks, avoidant behavior, reexperiencing, hyperarousal  Sleep disturbance, insomnia and hypersomnia secretion  Rare seizures, induction of mania, activation of suicidal ideation